1733 — Apex Biotechnology Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Annual cashflow statement for Apex Biotechnology, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	111	185	200	141	153
Depreciation
Amortisation
Non-Cash Items	20.6	30.3	1.42	29.3	9.19
Unusual Items
Other Non-Cash Items
Changes in Working Capital	44.2	-131	-268	-15.6	102
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	281	180	26.6	230	329
Capital Expenditures	-48.3	-30.2	-40.7	-25	-29.6
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	127	-4.83	-0.711	2.48	-5.96
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	78.8	-35	-41.4	-22.5	-35.6
Financing Cash Flow Items	0.363	-0.008	0.013	-0.016	-0.027
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-225	-351	-238	-168	-149
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	133	-232	-224	50.3	151